Geode Capital Management LLC Purchases 58,610 Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX)

Geode Capital Management LLC grew its position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) by 6.3% during the third quarter, Holdings Channel reports. The fund owned 982,729 shares of the company’s stock after purchasing an additional 58,610 shares during the period. Geode Capital Management LLC’s holdings in GoodRx were worth $6,823,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Barclays PLC grew its stake in GoodRx by 1,316.1% in the third quarter. Barclays PLC now owns 140,113 shares of the company’s stock worth $973,000 after purchasing an additional 130,219 shares during the period. Pier Capital LLC bought a new stake in shares of GoodRx during the 3rd quarter valued at $3,259,000. EP Wealth Advisors LLC purchased a new stake in shares of GoodRx in the 3rd quarter worth about $73,000. Point72 Asset Management L.P. bought a new position in shares of GoodRx in the 3rd quarter worth about $11,295,000. Finally, Centiva Capital LP lifted its position in GoodRx by 27.5% during the 3rd quarter. Centiva Capital LP now owns 66,233 shares of the company’s stock valued at $460,000 after acquiring an additional 14,287 shares during the period. Institutional investors own 63.77% of the company’s stock.

GoodRx Price Performance

Shares of GDRX opened at $4.45 on Friday. The firm has a market cap of $1.70 billion, a PE ratio of -148.33, a P/E/G ratio of 3.54 and a beta of 1.29. GoodRx Holdings, Inc. has a 1-year low of $4.09 and a 1-year high of $9.26. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. The firm has a fifty day simple moving average of $4.90 and a two-hundred day simple moving average of $6.69.

Analyst Upgrades and Downgrades

GDRX has been the topic of a number of recent research reports. Citigroup decreased their target price on shares of GoodRx from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th. Morgan Stanley lowered their price objective on GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 17th. Barclays cut their target price on GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. Finally, Mizuho assumed coverage on shares of GoodRx in a research report on Wednesday, December 4th. They set a “neutral” rating and a $5.00 price objective on the stock. Five analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.64.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.